Savara, Inc. (SVRA)
NASDAQ · Healthcare
$5.49-0.54%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.13B
- P/E ratio
- —
- EPS
- —
- Volume
- 1,350,277
- 52-week high
- —
- 52-week low
- —
- Open
- $5.54
- Day high
- $5.66
- Day low
- $5.41
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$118.84M | -$0.53 |
| 2024 | — | -$95.88M | -$0.48 |
| 2023 | — | -$54.7M | -$0.33 |
| 2022 | — | -$38.15M | -$0.25 |
| 2021 | — | -$43.01M | -$0.32 |
About Savara, Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
- CEO
- Matthew Pauls
- Employees
- 70
- Country
- US
- IPO date
- Apr 28, 2017
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Savara, Inc.'s stock price today?
- SVRA is trading at $5.49 as of Jul 20, 2026.
- What is Savara, Inc.'s market cap?
- Savara, Inc. (SVRA) has a market capitalization of $1.13B.
- Does Savara, Inc. pay a dividend?
- Savara, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Savara, Inc. in?
- Savara, Inc. operates in the Healthcare sector.